DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan(R) Kerastick(R) Photodynamic Therapy

DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan(R)
Kerastick(R) Photodynamic Therapy

Studies to Evaluate Broad Area Application of Levulan(R) Kerastick(R) for the
Treatment of Actinic Keratoses (AKs) of the Face or Scalp, and of Upper
Extremities

WILMINGTON, Mass., April 24, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals,
Inc.^® (Nasdaq:DUSA), a dermatology company that is developing and marketing
its Levulan^® Photodynamic Therapy (PDT) platform, announced today that
patient enrollment is complete in its Phase 2 clinical trial studying the
broad area application with 1, 2 and 3-hour (short) drug incubation for the
treatment of actinic keratoses (AKs) of the face or scalp. DUSA also completed
enrollment in its pilot Phase 2 clinical trial studying the safety and
efficacy of treating AKs on the upper extremities. Both studies are utilizing
the Levulan^®Kerastick^® (aminolevulinic acid HCl) for Topical Solution, 20%
with the BLU-U^® Blue Light Photodynamic Therapy Illuminator. The
FDA-approved labeling for Levulan^® Kerastick^® requires application of
Levulan^® to individual AK lesions, but in these clinical trials a broad area
application method is being utilized, where Levulan^® is applied to an entire
skin region.

The face/scalp exploratory study recruited patients at 13 clinical trial sites
across the United States, enrolling a total of 233 patients. This
vehicle-controlled study is designed to evaluate the effect of incubation
time, and spot versus broad area application method, on the safety and
efficacy of Levulan^® PDT in the treatment of multiple AKs of the face or
scalp and to investigate the potential for reduction of the occurrence of AKs
in the treatment areas. 

The extremities pilot study recruited patients at 3 clinical trial sites
across the United States, enrolling a total of 71 patients. This
vehicle-controlled study is designed to examine and compare the safety and
efficacy of the broad area application method of Levulan^®PDT for the
treatment of AKs on the upper extremities and to evaluate the effect of
occlusion on the safety and efficacy of Levulan^® PDT, using blue light after
a 3-hour incubation period.

"We are looking forward to the fourth quarter of 2012, when we anticipate
reporting the preliminary top-line statistical analysis of the trial results,"
stated Robert Doman, President and CEO of DUSA. "We are also excited because
the data from these clinical studies could provide us with significant further
insight into the potential clinical benefits of Levulan^® PDT."

About Actinic Keratoses (AKs)

Often called "sun spots," AKs are rough-textured, dry, scaly patches on the
skin that are caused by excessive exposure to ultraviolet light such as
sunlight and have the potential to progress to squamous cell carcinoma
(SCC)—the second most common skin cancer. They occur most often on the face,
scalp and ears. They can range in color from skin toned to reddish brown. They
can be as small as a pinhead or larger than a quarter. While most AKs remain
benign, approximately 10 percent develop into SCC within an average of two
years. Since there is no way to know ahead of time which ones will become
cancerous, it is very important to seek a dermatologist's care. Frequent skin
examinations are the key to early detection and prevention. It is estimated
that up to 58 million people in the United States have AKs.^1

About DUSA

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company
focused primarily on the development and marketing of its Levulan^®PDT
technology platform. Levulan^® Kerastick^®(aminolevulinic acid HCl) for
Topical Solution, 20% plus blue light illumination using DUSA's BLU-U^®Blue
Light Photodynamic Therapy Illuminator is currently approved for the treatment
of minimally to moderately thick actinic keratoses (AKs) of the face or
scalp.

^1Lewin Group. Burden of Skin Diseases. 2005.

DUSA is based in Wilmington, Mass. Please visit our website
atwww.dusapharma.com.Except for historical information, this news release
contains certain forward-looking statements that represent our current
expectations and beliefs concerning future events, and involve certain known
and unknown risk and uncertainties. These forward-looking statements relate to
the timing of reporting of trial results, the significance of the results.
These forward-looking statements are further qualified by important factors
that could cause actual results to differ materially from future results,
performance or achievements expressed or implied by those in the
forward-looking statements made in this release. These factors include,
without limitation, marketing of competitive products, actions by health
regulatory authorities, clinical trial risks, expenses and results, changing
economic conditions, the status of our patent portfolio, reliance on third
parties, and other risks and uncertainties identified in DUSA's Form 10-K for
the year ended December 31, 2011.

CONTACT: Robert F. Doman, President & CEO - 978.909.2216
         Richard Christopher, VP Finance & CFO - 978.909.2211
         Chad Rubin, Investor Relations Contact, The Trout
         Group LLC - 646.378.2947
         Cory Tromblee, Media Contact, MacDougall Biomedical
         Communications - 781.235.3060
 
Press spacebar to pause and continue. Press esc to stop.